164 related articles for article (PubMed ID: 37705009)
21. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Metaboproteomics of Burkitt's and Diffuse Large B-Cell Lymphoma Cell Lines and Primary Tumor Tissues Reveals Distinct Differences in Pyruvate Content and Metabolism.
Schwarzfischer P; Reinders J; Dettmer K; Kleo K; Dimitrova L; Hummel M; Feist M; Kube D; Szczepanowski M; Klapper W; Taruttis F; Engelmann JC; Spang R; Gronwald W; Oefner PJ
J Proteome Res; 2017 Mar; 16(3):1105-1120. PubMed ID: 28161958
[TBL] [Abstract][Full Text] [Related]
23. Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis.
Toyama K; Nakayama K; Terasaki S; Matsumura I; Kanaya S; Iino H; Noguchi H; Tahara K; Yoshida T; Saito A
J Clin Exp Hematop; 2023; 63(1):19-24. PubMed ID: 36990773
[TBL] [Abstract][Full Text] [Related]
24. Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues.
Yan WH; Jiang XN; Wang WG; Sun YF; Wo YX; Luo ZZ; Xu QH; Zhou XY; Cao JN; Hong XN; Li XQ
Front Oncol; 2020; 10():803. PubMed ID: 32582543
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
[TBL] [Abstract][Full Text] [Related]
27. Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies.
Decruyenaere P; Giuili E; Verniers K; Anckaert J; De Grove K; Van der Linden M; Deeren D; Van Dorpe J; Offner F; Vandesompele J
Front Oncol; 2023; 13():1221471. PubMed ID: 37954086
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma.
Kim HY; Jang MA; Kim HJ; Kim SJ; Kim WS; Kim SH
Blood Res; 2017 Sep; 52(3):193-199. PubMed ID: 29043234
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma.
Nakamura N; Hashimoto Y; Kuze T; Tasaki K; Sasaki Y; Sato M; Abe M
Lab Invest; 1999 Aug; 79(8):925-33. PubMed ID: 10462030
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases.
Tagawa H; Tsuzuki S; Suzuki R; Karnan S; Ota A; Kameoka Y; Suguro M; Matsuo K; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
Cancer Res; 2004 Sep; 64(17):5948-55. PubMed ID: 15342373
[TBL] [Abstract][Full Text] [Related]
32. [CD5-positive DLBCL: molecular basis and treatment strategies].
Miyazaki K
Rinsho Ketsueki; 2015 Aug; 56(8):1038-44. PubMed ID: 26345564
[TBL] [Abstract][Full Text] [Related]
33. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
[TBL] [Abstract][Full Text] [Related]
35. De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.
Kong SY; Cho EH; Woo HY; Park Q; Ko YH; Kim SH
J Korean Med Sci; 2004 Dec; 19(6):815-9. PubMed ID: 15608391
[TBL] [Abstract][Full Text] [Related]
36. [CD5- and CD10-positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88
Sasaki Y; Murai S; Okamura R; Uesugi Y; Shimada S; Watanuki M; Fujiwara S; Kawaguchi Y; Arai N; Yanagisawa K; Honma M; Yamochi T; Hattori N
Rinsho Ketsueki; 2023; 64(1):42-48. PubMed ID: 36775306
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
[No Abstract] [Full Text] [Related]
38. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.
Karnan S; Tagawa H; Suzuki R; Suguro M; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
Genes Chromosomes Cancer; 2004 Jan; 39(1):77-81. PubMed ID: 14603444
[TBL] [Abstract][Full Text] [Related]
39. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
40. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K
Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
